Jinxin Fertility Group Limited

HKSE 1951.HK

Jinxin Fertility Group Limited Return on Capital Employed (ROCE) for the year ending December 31, 2023: 3.64%

Jinxin Fertility Group Limited Return on Capital Employed (ROCE) is 3.64% for the year ending December 31, 2023, a 109.80% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Jinxin Fertility Group Limited Return on Capital Employed (ROCE) for the year ending December 31, 2022 was 1.73%, a -37.27% change year over year.
Jinxin Fertility Group Limited Return on Capital Employed (ROCE) for the year ending December 31, 2021 was 2.76%, a 18.02% change year over year.
Jinxin Fertility Group Limited Return on Capital Employed (ROCE) for the year ending December 31, 2020 was 2.34%, a -59.90% change year over year.
Jinxin Fertility Group Limited Return on Capital Employed (ROCE) for the year ending December 31, 2019 was 5.84%, a 9.31% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

HKSE: 1951.HK

Jinxin Fertility Group Limited

CEO	Mr. Yang Dong
IPO Date	June 25, 2019
Location	China
Headquarters	No. 301, North Jingsha Road
Employees	3,779
Sector	Finance
Industries Investment Banking & Asset Management Biotechnology Dental Care Hedge Funds Hospitals & Clinics Professional Services Research & Consulting Venture Capital

Description

Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and the United States. The company primarily offers two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. It also provides related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS. In addition, the company offers management services; medical services in the areas of gynecology, urology, and internal medicine; ambulatory surgery center facilities services; and ancillary medical services. Further, it offers pre-implantation genetic screening testing services; and engages in the investment management and management consultancy, and real estate development and operation activities. Jinxin Fertility Group Limited was founded in 2003 and is headquartered in Chengdu, China.

Key trends

Past 5 years